Medtronic is one of the world’s largest diversified medical-technology companies. Its fiscal 2026 results show a business with US$36.364 billion in net sales, a broad installed base across cardiovascular, neuroscience, surgical and diabetes care, and annual R&D spending approaching US$2.9 billion. In this article, Medtronic statistics refer primarily to the 52-week fiscal year ended 24 April 2026, not the calendar year.

The strongest top-line momentum came from Cardiovascular and Diabetes. The year also changed how investors should read the portfolio: following the March 2026 initial public offering of MiniMed, Medtronic stopped treating Diabetes as a reportable segment in its fourth quarter disclosure, although the business remained consolidated during FY2026.

Key Medtronic Statistics for 2026

·    FY2026 net sales reached US$36.364 billion, up 8.4% reported and 5.8% organic from FY2025.

·    Net income attributable to Medtronic was US$4.801 billion, versus US$4.662 billion in FY2025.

·    GAAP diluted EPS was US$3.73; non-GAAP diluted EPS was US$5.53.

·    Operating profit was US$6.467 billion, an 8.6% reported increase.

·    Operating cash flow totaled US$7.330 billion and company-defined free cash flow was US$5.426 billion.

·    R&D expense was US$2.873 billion, equal to 7.9% of net sales (calculated).

·    Medtronic employed more than 95,000 full-time people; 43% were based in the U.S. or Puerto Rico.

·    The company states that its technologies serve 82 million-plus patients; this is an operational reach measure, not a count of unique customers.

·    Cardiovascular was the largest operating business at US$13.976 billion, or 38.4% of consolidated sales (calculated).

·    Cardiovascular grew 12% reported; Diabetes grew 13% reported, the fastest of the four major operating businesses.

·    U.S. sales were US$18.103 billion and international sales were US$18.261 billion, almost an even split.

·    FY2026 dividends were US$2.84 per ordinary share; the Q1 FY2027 quarterly dividend rose to US$0.72.

·    Medtronic trades on the New York Stock Exchange under ticker MDT.

·    Key 2026 milestones included FDA approval of the OmniaSecure defibrillation lead and FDA clearance/CE Mark for Stealth AXiS.

·    Management’s FY2027 guidance, issued 3 June 2026, called for 6.75%–7.25% organic revenue growth and US$5.90–US$5.98 in adjusted diluted EPS.

Medtronic Company Profile

Medtronic Company Overview

Medtronic designs, manufactures and sells implantable devices, capital equipment, instruments, consumables, software and monitoring systems. Hospitals and clinicians use its products in cardiology, cardiac surgery, vascular intervention, neurosurgery, spine surgery, pain management, general surgery, intensive care and diabetes management. Patients also interact directly with long-duration technologies such as pacemakers, neurostimulators, insulin pumps and connected monitoring systems.

The customer base includes hospitals, ambulatory surgery centers, physician practices, distributors, purchasing organizations and public health systems. Revenue comes from a mix of implanted devices, disposable instruments and sensors, service arrangements, software and repeat consumables. This combination creates both procedure-sensitive sales and recurring demand tied to installed platforms.

At FY2026 year-end, the reporting structure comprised Cardiovascular, Neuroscience and Medical Surgical. Diabetes remained an operating business but was aggregated with “Other” after Medtronic sold 10% of MiniMed through an IPO and stated its intention to divest the remaining interest. That distinction matters when comparing segment disclosures across years.

History of Medtronic

Medtronic Revenue Statistics

Net sales declined 1.4% in FY2023, then resumed growth. FY2024 and FY2025 increased 3.6% each on a calculated reported basis. FY2026 accelerated to 8.4% reported, while Medtronic’s organic measure was 5.8%. Reported growth benefited from foreign exchange and a US$39 million Italian payback adjustment; organic growth removes currency and specified inorganic or accounting effects.

Cardiac ablation, leadless pacing, structural heart products, renal denervation, neuromodulation, monitoring, surgical technologies and diabetes systems supported growth. The filing also identifies constraints including tariffs, foreign exchange volatility, product mix, supply availability, reimbursement and procedure trends.

Chart 1. Medtronic Annual Revenue, FY2022–FY2026

Axis labels: X-axis: fiscal year; Y-axis: net sales | Units: US$ billion | Reporting period: Fiscal years ended April 2022 through April 2026

Insight: FY2026 produced the strongest reported annual growth in the five-year series.

Medtronic Profit and Earnings Statistics

Profit growth was slower than revenue growth at the bottom line. GAAP net income rose 3.0% and diluted EPS rose 3.3% in FY2026. The operating margin was approximately 17.8% in both FY2025 and FY2026 when calculated from GAAP operating profit and sales. Adjusted operating margin fell 130 basis points, reflecting investment, tariffs and other operating factors described by management.

Medtronic Revenue by Business Segment

Cardiovascular was the largest business. Within it, Cardiac Rhythm & Heart Failure generated US$7.504 billion, Structural Heart & Aortic US$3.817 billion, and Coronary & Peripheral Vascular US$2.656 billion. Neuroscience included Cranial & Spinal Technologies (US$5.222 billion), Specialty Therapies (US$2.997 billion) and Neuromodulation (US$2.068 billion).

Medical Surgical comprised Surgical & Endoscopy (US$6.764 billion) and Acute Care & Monitoring (US$2.051 billion). Diabetes sales reached US$3.112 billion, but the company no longer presented Diabetes as a reportable segment at year-end because of the MiniMed separation pathway.

Chart 2. Medtronic Revenue by Business Segment

Axis labels: Slices: operating business | Units: US$ billion and percentage of total | Reporting period: FY2026 ended 24 April 2026

Insight: Cardiovascular contributed about 38% of consolidated FY2026 net sales.

Medtronic Revenue by Geography

Medtronic’s audited FY2026 filing uses U.S. and international as the directly comparable consolidated geography categories. It does not provide a full audited split between developed markets outside the U.S. and emerging markets in the segment table; therefore, no artificial regional estimates are added here. International growth outpaced U.S. growth, helped partly by currency translation.

Chart 4. Medtronic Geographic Revenue Distribution

Axis labels: X-axis: net sales; Y-axis: geography | Units: US$ billion | Reporting period: FY2026 ended 24 April 2026

Insight: International revenue narrowly exceeded U.S. revenue.

Medtronic Employee Statistics

The filing does not publish a precise FY2026 headcount or a full workforce split by manufacturing, research and commercial function. It reports that 43% of full-time employees were in the U.S. or Puerto Rico. Based on the “more than 95,000” disclosure, that percentage implies at least about 40,850 people in those locations, but the company does not provide an exact number.

Medtronic reported 100% U.S. pay equity for gender and ethnically diverse employees and 99% global gender pay equity for its most recently reported period. These are company-reported pay-equity measures, not workforce representation percentages. Restructuring charges totaled US$249 million in FY2026, but the 10-K does not equate that amount to a specified number of job reductions.

Medtronic Research and Development Statistics

R&D spending rose to a five-year high of US$2.873 billion in FY2026, up 5.2% from FY2025 on a calculated basis. The portfolio spans pulsed-field ablation, pacing and defibrillation, transcatheter heart valves, renal denervation, spine navigation, deep-brain and spinal-cord stimulation, diabetes automation, surgical robotics, artificial intelligence and connected-care software.

Medtronic’s investor site reports 180-plus active clinical trials in FY2026. The company also uses funded R&D arrangements; these should not be confused with GAAP R&D expense. For example, a US$157 million charge tied to a funded-development royalty obligation was recorded in other operating expense in FY2026.

Chart 3. Medtronic R&D Expenditure, FY2022–FY2026

Axis labels: X-axis: fiscal year; Y-axis: R&D expense | Units: US$ billion | Reporting period: Fiscal years ended April 2022 through April 2026

Insight: R&D expense increased by roughly US$380 million over five years.

Medtronic Product and Therapy Statistics

Cardiac rhythm. Pacemakers, leadless pacing systems, implantable cardioverter-defibrillators, cardiac-resynchronization devices, insertable monitors, leads and remote-care systems.

Cardiovascular intervention. Transcatheter and surgical valves, aortic stent grafts, coronary and peripheral devices, cardiac ablation systems and the Symplicity renal-denervation platform.

Diabetes. MiniMed insulin pumps, continuous glucose-monitoring sensors, infusion sets and automated insulin-delivery software.

Surgery and monitoring. LigaSure energy devices, stapling and suturing products, endoscopy tools, Nellcor oximetry, Microstream capnography, airway products and advanced monitoring sensors.

Neuroscience. Spine and cranial implants, imaging and navigation, deep-brain stimulation, spinal-cord stimulation and peripheral nerve stimulation.

Robotics and digital. The Hugo robotic-assisted surgery system, Stealth navigation, Touch Surgery Enterprise video analytics and connected device-management software.

Product breadth reduces dependence on any single therapy, but it also raises regulatory, manufacturing and quality-system complexity. Utilization varies with procedure volumes, clinical evidence, physician training, hospital capital budgets and reimbursement.

Medtronic Patent and Innovation Statistics

Medtronic’s FY2026 Form 10-K states that patents, trademarks, trade secrets and know-how are important, but it does not publish a reconciled count of active patents, granted patents, applications or patent families. Accordingly, this article does not present a headline patent total. Public patent databases can change as applications publish, rights lapse and ownership records update.

A granted patent is an issued right in one jurisdiction; an active patent is an issued patent still in force; an application is pending and may never issue; and a patent family groups related filings that claim common priority. Adding these categories together would double-count inventions and misstate portfolio size. Innovation evidence is therefore discussed through R&D expense, clinical trials, regulatory decisions and product launches.

Medtronic Acquisitions, Divestitures, and Partnerships

Medtronic Regulatory Approvals and Product Developments

“Approval,” “clearance,” “CE Mark,” “submission” and “launch” are not interchangeable. Approval generally reflects an FDA premarket approval pathway for higher-risk devices or supplemental indications; 510(k) clearance establishes substantial equivalence; CE Mark indicates conformity with European requirements; a submission remains under review; and a commercial launch describes market availability.

Medtronic Competitor Comparison

This comparison is directional. Abbott and Philips include businesses beyond implanted devices; Johnson & Johnson does not publish a MedTech-only employee count; Siemens Healthineers reports in euros; and fiscal year-ends differ. Revenue scale alone does not measure market share in a specific therapy.

Medtronic Market Position

Medtronic’s competitive position rests on broad clinical coverage, an international commercial network, physician relationships, manufacturing scale and a large installed base. Recurring opportunities arise from sensors, catheters, disposables, replacement implants, service and software associated with durable platforms.

The same breadth creates exposure. Regulatory remediation, recalls and quality failures can interrupt supply or damage trust. Reimbursement changes can slow adoption, while hospital capital constraints affect robotic and navigation platforms. Currency movements matter because international revenue represented 50.2% of FY2026 sales. Tariffs affected FY2026 margins, and the company also faces component availability, cyber, tax and geopolitical risks.

Competition is therapy-specific. Abbott, Boston Scientific and Edwards compete in major cardiovascular categories; Stryker and Johnson & Johnson compete in surgery, spine and neurotechnology; insulin-delivery competitors pressure MiniMed; and imaging or monitoring companies compete in connected hospital workflows. No unsupported company-wide market-share percentage is used here.

Recent Medtronic Developments in 2026

Future Outlook

On 3 June 2026, management guided to FY2027 organic revenue growth of 6.75%–7.25% and adjusted diluted EPS of US$5.90–US$5.98. The organic growth range includes a 53rd week and Diabetes revenue for the full fiscal year, while excluding foreign exchange and “Other” revenue. Guidance is a management forecast, not a confirmed result.

Potential growth drivers include pulsed-field ablation, leadless pacing, transcatheter valves, renal denervation, neuromodulation, surgical navigation, Hugo robotics and diabetes automation. Material uncertainties include execution of the MiniMed divestiture, integration of acquisitions, tariffs, foreign exchange, price pressure, reimbursement, clinical and regulatory outcomes, supply resilience, cybersecurity, product quality and litigation or tax exposures.

Frequently Asked Questions About Medtronic Statistics

What is Medtronic’s revenue in 2026?

Medtronic reported US$36.364 billion in net sales for fiscal 2026, the 52-week period ended 24 April 2026. Revenue increased 8.4% as reported and 5.8% organically. The figure is an audited fiscal-year result, not calendar-year 2026 revenue or a management forecast.

How many employees does Medtronic have?

Medtronic reported more than 95,000 full-time employees in its FY2026 Form 10-K. The filing states that 43% were based in the United States or Puerto Rico. It does not publish an exact global headcount or a complete breakdown by manufacturing, R&D and commercial function.

Where is Medtronic headquartered?

Medtronic plc is legally domiciled in Ireland, with its registered office in Galway. Its principal operational headquarters remains in the Minneapolis area of Minnesota, United States. This dual description reflects the corporate structure created after the company completed the Covidien transaction in 2015.

Who is Medtronic’s CEO in 2026?

Geoff Martha was Medtronic’s chairman and chief executive officer as of 12 August 2026. Leadership can change, so publication-date context matters. This article verifies the position through Medtronic’s FY2026 filing and investor materials rather than relying on an undated third-party company profile.

What are Medtronic’s major business segments?

At FY2026 year-end, Medtronic’s reportable segments were Cardiovascular, Neuroscience and Medical Surgical. Diabetes remained an operating business but was aggregated with Other after the MiniMed IPO because Medtronic intended to divest its remaining interest. Earlier-year segment presentations may therefore differ.

Which Medtronic segment generates the most revenue?

Cardiovascular was the largest business in FY2026, generating US$13.976 billion in net sales. That equaled approximately 38.4% of consolidated revenue, calculated from audited figures. Its divisions included Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular.

How much does Medtronic spend on research and development?

Medtronic recorded US$2.873 billion in GAAP research and development expense in FY2026. That represented approximately 7.9% of net sales, calculated as R&D divided by revenue. Spending covered cardiovascular, neuroscience, surgical, diabetes, robotics, digital and clinical-development programs.

In how many countries does Medtronic operate?

Medtronic describes a global commercial and operating footprint, but its FY2026 Form 10-K does not state one precise, audited country count. The company often uses broad reach language in corporate materials. This article therefore reports U.S. and international revenue without converting marketing descriptions into an exact country statistic.

What are Medtronic’s most important products?

Major platforms include pacemakers and defibrillators, Micra leadless pacing, heart valves, ablation systems, Symplicity renal denervation, spine and cranial technologies, deep-brain and spinal-cord stimulation, LigaSure surgical instruments, Nellcor monitoring, Hugo robotic-assisted surgery and MiniMed insulin-delivery systems.

Who are Medtronic’s main competitors?

Competitors vary by therapy. Important peers include Abbott, Boston Scientific, Stryker, Johnson & Johnson MedTech, Edwards Lifesciences, Becton Dickinson, Baxter, Siemens Healthineers and Philips. No single company competes equally across every Medtronic category, so category-level evidence is more useful than a company-wide market-share claim.

What is Medtronic’s stock ticker?

Medtronic plc ordinary shares trade on the New York Stock Exchange under MDT. Investors should distinguish the ticker from the company’s Irish legal domicile and U.S. operational headquarters. Market price and market capitalization change continuously and are therefore not fixed in this publication.

What is Medtronic’s outlook for its next fiscal year?

Management’s 3 June 2026 guidance called for 6.75%–7.25% organic revenue growth and US$5.90–US$5.98 adjusted diluted EPS in FY2027. The revenue range includes a 53rd week and full-year Diabetes revenue. Guidance depends on business, currency, regulatory and macroeconomic assumptions and is not guaranteed.

Conclusion

The central Medtronic statistics for 2026 show a company with US$36.364 billion in annual net sales, US$4.801 billion in attributable net income, more than 95,000 employees and US$2.873 billion in R&D expense. Cardiovascular led revenue, while international sales slightly exceeded U.S. sales.

Growth opportunities span ablation, pacing, structural heart, renal denervation, neuroscience, robotics and connected care. Investors and healthcare buyers must balance that pipeline against integration, separation, reimbursement, quality, cybersecurity, supply-chain, tariff and currency risks. Because the MiniMed transaction changed segment reporting, future comparisons should use consistent portfolio definitions.